Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592 is registered in ClinicalTrials.gov with Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) as lead sponsor.

NCT NCT07001592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07001592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase
Phase 1
Overall status
Recruiting
Start date
May 6, 2025
Completion date
May 31, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric adenocarcinoma, gastric cancer, gastric neoplasms, liver cancer, liver metastasis, msi-h, mss, mss-crc, peritoneal cancer, peritoneal carcinoma, peritoneal metastases